By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.
What Root to Rx Is
Free, every week, no sponsor.
Monday, The Root Room. You watch a real health claim try to work on somebody.
Wednesday, Plain Talk. One health topic from the news, taken apart in plain language, with the receipts at the foot of it.
Tuesday and Friday, The Open Site File. What the job actually looks like from inside a clinical trial site. If you or anyone you know has ever thought about moving into clinical research coordinating, start there.
Sunday, The Roots, on LinkedIn. A weekly letter for the people who get asked, the ones whose family treats them as the medical desk.
The 30 second version
Peptides like BPC-157 are being sold as anti-aging and recovery shots, often by clinics and longevity influencers.
Most have lab and animal studies behind them and very little in people. Plenty of buyers know that and do it anyway, because wanting to look and feel younger is human.
This week you watch the pitch work on someone smart. Wednesday's Plain Talk lays out the evidence. The question to carry: which one was tested?
Two of our helpers are sitting in with you. Sam the Skeptic, who asks how do we know and never lets anyone skip the question, including us. And Rooty the Researcher, who brings the receipts. Sam asks and Rooty answers. That's how this works every week.
The Consultation Room
The room is designed to feel like wellness, not medicine.
The room doesn't look like a doctor's office, and that's on purpose.
There's a living wall of ferns, a cold plunge behind frosted glass, and a menu on the wall that reads like a coffee shop: Recovery. Glow. Sleep. Longevity. Dana is 46. She sells real estate, runs three mornings a week, and has started noticing her face in her own listing photos. She booked the consult after a podcast she likes spent an hour on peptides.
Marcus founded the clinic. He's warm, quick, and clearly believes every word. He's been on what he calls his stack for two years, and he shows her his before and after on his phone.
"This one's BPC-157," he says, tapping the menu. "People call it the Wolverine peptide. Tendons, joints, gut, recovery. This one's GHK-Cu, for skin and hair. And here's the thing people miss. Your body already makes peptides. Insulin is a peptide. Ozempic is a peptide. We're just giving your body more of what it already knows how to use."
Sam leans toward Rooty. "That insulin line was good."
"It was very good," Rooty says. "Hold onto it. We'll come back to it."
She Already Knows There Are No Human Trials
Here's the part that surprises people. Dana isn't naive. She did her reading before she came.
"I know there aren't real trials," she says. "I looked. It's mostly rats. I don't care. I'm 46. If I wait for the studies, I'll be 60."
Marcus nods like he's heard it a hundred times, because he has.
Sam turns to Rooty. "So what do we say to that? She knows."
"We don't say she's vain," Rooty says. "Wanting to look and feel younger isn't a character flaw. It might be the most human thing in this room. And she's right that waiting has a cost. What she doesn't have yet is a clear picture of what no human trials actually means. It isn't a missing certificate. It's missing information she'd want."
What "No Human Trials" Actually Means
Research grade, the label says. It doesn't say who checked.
Rooty counts it off.
"It means no well designed study has worked out the right dose in people. The number on Marcus's menu came from somewhere, just not from a study that measured what that amount does in a human body."
"It means nobody knows what year two looks like. Or year five."
"And it means nobody outside the seller has checked what's in the vial. When FDA scientists reviewed BPC-157 this summer, one of them asked, in the meeting, what BPC-157 even is. He said people don't agree on its makeup, and that you can't set quality standards until you know."
Sam blinks. "The regulator asked what it is?"
"On the record."
What a Real Receipt Looks Like
For comparison, here's what a new drug has to show before one person gets one dose. Animal studies in two species. Safety tests on the heart, the lungs and the brain. A starting dose worked out from all of that and then divided by ten, so the first person in a study gets a fraction of a dose that already did nothing detectable to the most sensitive animal tested. Then trials in people, usually in phases, to show the drug works and is safe enough.
None of that is red tape for its own sake. Each step was added after something went wrong without it, and our Version History page tells those stories. Insulin went through that. So did semaglutide, the drug in Ozempic. That's exactly what Marcus's best line leaves out.
Then Dana Asks the Question
"Is it even legal?" Dana asks.
Marcus has an answer ready, and it's partly true. "The FDA just voted for it. This summer."
Rooty winces a little, because this is where it gets slippery.
"Here's what happened," he tells Sam. "In July, an FDA advisory committee voted to recommend letting compounding pharmacies make six of these peptides, BPC-157 included. The BPC-157 vote was 8 to 6. The FDA's own staff had recommended against every one. And the committee only advises. The FDA hasn't acted on it. Even if it does, that would let licensed pharmacies make it with a prescription. It still wouldn't be an approval, and it wouldn't create the human trials."
"So 'the FDA voted for it' is..."
"A true sentence about an advisory vote, standing in for a claim about safety it never made."
Then Dana asks where the vials come from. Marcus says they're research grade.
"Research grade usually means research use only," Rooty says quietly. "That's a phrase from the rules for lab test kits. There's no research use only category for drugs. It isn't a lighter kind of medicine. It means the vial hasn't been through any drug review at all."
You can read more at: https://www.roottorx.com/t/peptides
What Dana Decides
She doesn't buy anything today. That isn't the point of the story, and it isn't a win.
What changes is how she's deciding. On the way out she asks Marcus two things she didn't walk in with: which of these has actually been tested in people, and who checked what's in the vial. He answers the first one honestly. He doesn't have an answer for the second.
She might still do it. Plenty of people will. But if she does, she'll be doing it with her eyes open, and hopefully she'll tell her doctor, before or after. That's easier on paper than out loud, which is why we made a free one page Medication and Supplement Log with room for peptides. If something is strong enough that you hope it changes your body, it's strong enough to tell your doctor about, so they can check for interactions.
Wednesday's Plain Talk, Peptides Explained, lays out what's actually known about BPC-157 and the others, where the FDA stands, and the Skeptic's Toolkit questions so you can decide for yourself.
The Black Box Warning: The Family Resemblance
The Family Resemblance. One member of the family did the work.
Black Box Warning
Tactic: The Family Resemblance.
Tool: point to a famous, proven member of a category, then let its evidence rub off on an unproven one.
Running it: "Insulin is a peptide." Also "Ozempic is a peptide," "your body already makes these," "it's natural."
This one works because every word is true. Insulin is a peptide. Your body does make thousands of them. The trick is in what the sentence asks you to assume next.
Move 1. Name the famous relative.
Put it this way. Your cousin being a surgeon doesn't mean you can do his job.
Move 2. Let the category carry the proof. "Peptides work" sounds like a finding. It's a family name. Each peptide has to earn its own evidence, the same way each drug does.
Put it this way. Every car on the road is a vehicle. That doesn't mean yours passed inspection.
Move 3. Skip the one question that would break it: which one was tested, and for what?
Put it this way. "Mushrooms are food" is true, right up until someone asks which mushroom.
The move to keep
Ask which one. Whenever a claim leans on a whole category, like peptides, natural compounds or plant extracts, bring it back down to the specific thing being sold and ask for its own receipts. The family's track record doesn't transfer.
Sam the Skeptic asks: "Which one, though?"
Take This One With You
You're going to hear both of these, and they need different answers.
When somebody says peptides are safe because insulin is a peptide:
Insulin earned its record in human trials, and so did the GLP-1 drugs. Being a peptide doesn't transfer that. Most of the trending ones, like BPC-157, have animal studies and very little in people. So the real question is which peptide, and tested for what.
When somebody says they know there are no trials and they're doing it anyway:
That's your call, and I get why. Just know what no trials means: nobody's worked out the dose in people, nobody knows what year two looks like, and nobody outside the seller checked what's in the vial. If you do it, tell your doctor what you're taking.
Save this. Send it the next time it comes up.
Notice what neither of those does. Neither one calls anybody vain, and neither one tells them what to do. The second one doesn't even argue. It just makes sure the decision is being made with the real picture.
That's the method. You're not trying to win. You're trying to make sure the person you care about is choosing with their eyes open, and still calls you afterward.
The Wall of Sams
Reply to this email or leave a comment on the newsletter: have you been pitched a peptide, by a clinic, a coach or a podcast? What did they say it would do, and what did they show you?
Want to practice the move before you need it? Got Skepticism is our two minute game that runs any claim through five questions, including the one Sam just used: which one, though? Free, no signup, at openlabelmedia.com/games.
Send this to one person
Not "someone who should know." One person. The friend who just started peptide shots. The sibling who keeps sending you longevity podcasts. Use your own link below and it counts toward your Series 1 card.
New here? Root to Rx is free, every week. Monday, The Root Room: you watch a real health claim try to work on someone. Wednesday, Plain Talk: the same topic taken apart in plain language. Tuesday and Friday, The Open Site File: the job from inside a trial site. Sunday, The Roots, on LinkedIn. Written by a clinical researcher, at RootToRx.com.
Between issues, the free tools live on the site. The Field Guide has printable patient logs and the full Skeptic's Toolkit at roottorx.com/field-guide. If you or someone you love is looking for a trial, there's a walkthrough for finding one near you at roottorx.com/clinical-trial-registries. And if you've ever wondered why clinical research has the rules it does, Version History tells that story at roottorx.com/version-history. The tees and mugs that help support the work are at shop.roottorx.com.
For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.
Instagram: instagram.com/roottorx | LinkedIn: linkedin.com/company/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | Subscribe: RootToRx.com
You are receiving this because you subscribed at roottorx.com.
Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.
Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States